A novel mitoNEET ligand, TT01001, improves diabetes and ameliorates mitochodnrial function in db/db mice

The mitochondrial outer membrane protein mitoNEET is iron containing protein and a novel target of type II diabetes drug pioglitazone. mitoNEET regulates energy metabolism in mitochondria, and several small-molecule compounds have been identified as mitoNEET ligands using structure-based design or virtual docking studies. However, there are no reports about their therapeutic potential in type II diabetes models. Recently, we synthesized a novel small molecule, TT01001, designed on the basis of pioglitazone structure. In this study, we assessed the pharmacological properties of TT01001 in both in vitro and in vivo studies. We found that TT01001 bound to mitoNEET without PPARγ activation effect. In type II diabetes model db/db mice, TT01001 improved hyperglycemia, hyperlipidemia, and glucose intolerance, and its efficacy was equivalent to that of pioglitazone, without the pioglitazone-associated weight gain. Regarding skeletal muscle, mitochondrial complex II + III activity and amount of iron was significantly increased in db/db mice. We also found that TT01001 significantly suppressed the elevated activity of the complex II + III, and inhibited iron induced lipid peroxidation in isolated mitochondria. These results suggest that TT01001 improved type II diabetes without causing weight gain and ameliorated mitochondrial function of db/db mice. This is the first study that demonstrates the effects of a mitoNEET ligand on glucose metabolism and mitochondrial function in an animal disease model. These findings support targeting mitoNEET as a potential therapeutic approach for the treatment of type II diabetes.